Policy
White House pulls nomination for FDA nominee Overton
BioPharma Dive · By Jonathan Gardner ·
The Brief
- The White House has withdrawn its nomination of Heidi Overton to lead the FDA, according to BioPharma Dive on 2026-11-18.
- BioPharma Dive reports that analysts say the withdrawal shouldn't disrupt the agency.
- The end of Overton's candidacy likely means a Democrat-controlled Congress will choose the FDA's next leader.
Why it matters
FDA leadership is unsettled again, and the agency's next commissioner will shape how it regulates drugs and medical products that science readers follow.
Who’s affected
- readers following US drug regulation
- biopharma companies awaiting FDA leadership
- #fda
- #drug regulation
- #nominations
- #us policy
- #heidi overton
The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.